Thesis

77 Grey zone amyloid burden 50. Duara R, Loewenstein DA, Lizarraga G, Adjouadi M, Barker WW, Greig-Custo MT, et al. Effect of age, ethnicity, sex, cognitive status and APOE genotype on amyloid load and the threshold for amyloid positivity. Neuroimage Clin. 2019;22:101800-. 51. Schreiber S, Landau SM, Fero A, Schreiber F, Jagust WJ, Initiative ftAsDN. Comparison of Visual and Quantitative Florbetapir F 18 Positron Emission Tomography Analysis in Predicting Mild Cognitive Impairment Outcomes. JAMA neurology. 2015;72(10):1183-90. 52. Ossenkoppele R, Jansen WJ, Rabinovici GD, Knol DL, van der Flier WM, van Berckel BN, et al. Prevalence of amyloid PET positivity in dementia syndromes: a metaanalysis. Jama. 2015;313(19):1939-49. 53. Klunk WE, Koeppe RA, Price JC, Benzinger TL, Devous MD, Sr., Jagust WJ, et al. The Centiloid Project: standardizing quantitative amyloid plaque estimation by PET. Alzheimer’s & dementia : the journal of the Alzheimer’s Association. 2015;11(1):1-15.e1-4. 54. Navitsky M, Joshi AD, Kennedy I, Klunk WE, Rowe CC, Wong DF, et al. Standardization of amyloid quantitation with florbetapir standardized uptake value ratios to the Centiloid scale. Alzheimer’s & dementia : the journal of the Alzheimer’s Association. 2018;14(12):1565-71. 55. Hanseeuw BJ, Malotaux V, Dricot L, Quenon L, Sznajer Y, Cerman J, et al. Defining a Centiloid scale threshold predicting long-term progression to dementia in patients attending the memory clinic: an [18F] flutemetamol amyloid PET study. European journal of nuclear medicine and molecular imaging. 2020. 3

RkJQdWJsaXNoZXIy MjY0ODMw